§174A R&D Amend: The OBBBA Refund Window for Small Businesses Closes July 6, 2026

From 1954 through 2021, IRC §174 let businesses immediately deduct research and experimentation expenditures in the year incurred. It was a clean rule with a long history; R&D-heavy companies built their tax planning around the immediate deduction.

TCJA, signed in 2017, included a delayed change to §174 that took effect for tax years beginning after 12/31/2021. Starting in 2022, businesses had to capitalize domestic R&E and amortize it over 5 years (15 years for foreign R&E). The change was a revenue-raising offset for other provisions and was widely expected to be repealed before it took effect. It was not. By 2023, the result was that thousands of small software and engineering companies discovered they owed federal tax on what they thought was a break-even or losing year, because the §174 capitalization rule had turned a cash deduction into a 5-year amortization.

OBBBA 2025 (One Big Beautiful Bill Act) restored immediate domestic expensing under a new §174A for tax years after 12/31/2024. Foreign R&E remains on the 15-year amortization schedule under the existing §174. The bill also opened the retroactive amend door for small businesses, which is the time-sensitive piece.

The math has two pieces. First, the deferred-deduction recovery: the R&D you capitalized in 2022 and was amortizing over 5 years gets deducted immediately in the amended return, generating a refund for the tax overpayment caused by the capitalization. Same for 2023 and 2024. Second, depending on the entity type, the refund flows directly to the C-corp or to the pass-through owner's personal return via amended K-1s.

A worked example. A C-corp software company spent $500,000 on domestic R&D in each of 2022, 2023, and 2024. Under TCJA §174, only $50,000 was deductible in 2022 ($500K / 5 years, half-year convention), $150,000 in 2023, $250,000 in 2024 (cumulative across the three years), with the rest stranded as future amortization. Amending under the OBBBA election expenses all $1.5M immediately across the three years. At a 21% federal C-corp rate, that is roughly $230,000 to $250,000 of additional refund in aggregate across the three amended returns, depending on how the deferred amortization had been running.

The catalog Signal uses to score these on inbound diagnostics carries a typical recovery range of $25,000 to $1,000,000, one-time. The low end is a smaller software or engineering shop with modest R&D spend; the high end is a mid-market manufacturer or biotech with multi-million-dollar R&D programs.

The recovery stacks with the §41 R&D Credit. Most companies that capitalized R&D under §174 should also have been claiming the §41 credit, and many under-claim it (typical range $25,000 to $250,000 per year in the Signal catalog). The combined recovery, when both are properly chased through the amend window, is often the largest one-time refund opportunity in the small-business catalog.

1. Missing the 7/6/2026 deadline. The single biggest miss. The retroactive amend window is short, the practitioner community is still catching up to the transition guidance, and many small-business owners do not know the door exists. After 7/6/2026, the refund evaporates.
2. Failing to make the §174A election on a timely 2025 return. The election is required to be made on the 2025 return; it is not automatic. Most software handles the election once you flag it, but if you do not flag it, the election will not happen.
3. Commingling foreign R&E with domestic. Foreign R&E still requires 15-year amortization under §174. Only domestic R&E qualifies for the §174A immediate expensing and the retroactive election. Companies with both need to split the spend cleanly.
4. Not coordinating with the §41 R&D Credit. The credit and the expense deduction interact: the §280C(c) basis-reduction election (or its equivalent) coordinates the credit with the deduction so the same dollar is not double-counted. Amending without coordinating the credit recompute leaves money on the table or, worse, generates a follow-on amend.
5. Forgetting that pass-through amends flow through to owners. An amended 1120-S or 1065 generates amended K-1s, which require amended 1040s for every owner. The refund flows through; so does the work.

OBBBA 2025 is new. The transition guidance was issued in stages. The amend mechanics are non-trivial. For a generalist preparer who runs 300 returns a year, the §174A retroactive election sits in the most awkward zone: a high-stakes, time-pressured, one-time-only opportunity that requires a project to execute, not a check-box to add to next year's return.

The three reasons it gets missed:

1. It is amend work, not return work. Amend projects do not bill at the same rate as a fresh return. For a high-volume preparer, the economics of stopping mid-busy-season to amend three years of prior returns are not appealing.
2. It requires coordination across years. The 2022 amend changes the 2023 starting point, which changes the 2024 starting point, which changes the 2025 starting point. The work compounds.
3. The deadline is short and the guidance is fresh. Many preparers are still digesting OBBBA 2025. By the time the firm comfortably runs the analysis, the deadline has passed.

This is the cleanest case in the catalog where the "second opinion" frame catches a refund that the original preparer either is not chasing or has not had the bandwidth to chase. The Signal diagnostic checks for §174 capitalization on 2022-2024 returns as a standard scan item.